Key result
Selective EP4 receptor agonists attenuate inflammatory cytokines and chemokines by suppressing macrophage activation in inflammatory heart diseases such as cardiac ischemia, transplant rejection, and myocarditis.
This review highlights the potential therapeutic role of selective EP4 agonists in attenuating inflammation in cardiovascular diseases such as myocarditis and myocardial ischemia.
Hypothesis-generating for EP4 agonists in myocarditis and ischemia; clinical trials needed before any practice change.
Prostaglandin E2 (PGE(2)) is produced in inflammatory responses and regulates a variety of immunological reactions through 4 different receptor subtypes; EP1, 2, 3 and 4. However, the precise role of each receptor in cardiovascular disease has not yet been elucidated. Enhanced expression of some EPs has been observed in clinical and experimental cardiovascular diseases. EP agonists have been developed to clarify the role of each receptor. Recently, we developed a novel selective agonist to examine the effects of EP4 on cardiac transplantation, myocardial ischemia, and myocarditis. Of note, a selective EP4 agonist attenuated inflammatory cytokines and chemokines via attenuation of macrophage activation in inflammatory heart diseases. In this review article, we discuss the effects of PGE(2) receptor agonists on the development of cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
Suzuki et al. (2011) conducted a review in Cardiovascular diseases (myocardial ischemia, cardiac transplantation, myocarditis). Prostaglandin E2 receptor agonists (focus on EP4 agonists) was evaluated. Selective EP4 receptor agonists attenuate inflammatory cytokines and chemokines by suppressing macrophage activation in inflammatory heart diseases such as cardiac ischemia, transplant rejection, and myocarditis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: